摘要:
The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis.It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hydridization probes, derived from the RNA of HIV-2.
摘要:
The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis.It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.
摘要:
The invention relates to a composition comprising at least one antigen, wherein the antigen is a protein or glycoprotein of a HIV-2 virus, wherein the HIV-2 virus has infectious properties with respect to human T4 lymphocytes and the essential morphological or immunological property of at least one of the retroviruses deposited at the CNCM under No. I-502, I-532, I-642, and I-643. It also relates to a process for the production of HIV-2 retrovirus antigens by lysing cells infected with the virus or lysing purified virus and recovering the antigens.
摘要:
The claimed invention is directed toward in vitro methods for the detection of human immunodeficiency virus type 2 (HIV-2) antibodies employing polypeptide fragments of HIV-2 Gag.
摘要:
Methods for producing the newly discovered HIV-2 retrovirus and its antigens are provided. The antigens are obtained from various HIV-2 retroviruses. The antigen compositions comprise a lysate of an HIV-2 retrovirus, a protein of an HIV-2 retrovirus, or a glycoprotein of an HIV-2 retrovirus. Specifically, the antigen composition can comprise p12, p16, p26, gp32, gp42, and gp140.
摘要:
The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.
摘要:
The present invention relates to a method of vaccination via hair follicles that makes it possible to target vaccine components to the antigen-presenting cells in order to induce a protective and effective immune response against pathogens.
摘要:
The present invention relates to a method of vaccination via hair follicles that makes it possible to target vaccine components to the antigen-presenting cells in order to induce a protective and effective immune response against pathogens.
摘要:
The invention concerns treatment of infectious and tumoral pathologies comprising a anti-infective and/or anti-tumoral chemotherapeutic treatment phase inducing resistance mutations and a therapeutic vaccination phase directed against said resistance mutations and the agents used in said treatment More particularly, the invention concerns peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence and comprising at least a mutation with respect to said wild sequence of said enzyme, mutation induced in response to treatments by nucleoside and non-nucleoside analogues of the HIV reverse transcriptase. The invention also concerns a pharmaceutical composition or vaccine based on said peptides, for inducing an immune response specific of said mutated sequences and for enhancing or prolonging the efficiency of treatments with nucleoside or non-nucleoside analogues of the HIV reverse transcriptase. The invention further concerns epitopes derived from said peptide sequences to evaluate the specific immune response following the vaccine injection.